Medifast (NYSE:MED) Releases FY 2026 Earnings Guidance

Medifast (NYSE:MED) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of -2.750–1.55 for the period, compared to the consensus EPS estimate of -1.380. The company issued revenue guidance of $270.0 million-$300.0 million, compared to the consensus revenue estimate of $355.1 million. Medifast also updated its Q1 2026 guidance to -0.700–0.15 EPS.

Medifast Price Performance

Shares of MED traded up $0.01 on Tuesday, reaching $10.78. 176,137 shares of the stock traded hands, compared to its average volume of 223,627. The firm has a market cap of $118.48 million, a price-to-earnings ratio of 1,078.00 and a beta of 0.53. Medifast has a 12 month low of $10.10 and a 12 month high of $16.45. The stock’s 50-day moving average price is $11.35 and its 200-day moving average price is $12.32.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Weiss Ratings reissued a “sell (d)” rating on shares of Medifast in a report on Thursday, January 22nd. Wall Street Zen raised Medifast from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Reduce” and a consensus price target of $16.50.

Key Medifast News

Here are the key news stories impacting Medifast this week:

• Positive Sentiment: Q4 revenue roughly in line / slight beat — Medifast reported Q4 2025 revenue of $75.1M, modestly above the Street view and company press materials. BusinessWire: Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Liquidity and balance-sheet notes — cash & cash equivalents remain around ~$89M and total liabilities declined year-over-year, which cushions near-term liquidity risk. QuiverQuant: Q4 2025 Earnings
• Neutral Sentiment: Conference materials and call available — management hosted an earnings call and posted slides/transcript that investors can use to assess cost actions and go‑forward plans. Yahoo: Q4 2025 Earnings Call Transcript
• Negative Sentiment: Material downward guidance for 2026 — Medifast cut Q1 2026 and FY 2026 guidance well below consensus: Q1 revenue guided to roughly $65M–$80M (consensus ~ $78.1M) and FY revenue to $270M–$300M (consensus ~ $355M). EPS guidance ranges for Q1 and FY were also lowered materially, signaling a tougher year ahead (company guidance released 2/17/26).
• Negative Sentiment: Widening GAAP losses and EPS pressure — the company reported a substantial GAAP net loss (company disclosed ~$18.1M net loss; ~-$1.65/share) and operating losses widened versus prior year, which contrasts with some outlets’ adjusted metric reporting and is weighing on sentiment. QuiverQuant: Q4 2025 Earnings
• Negative Sentiment: Operating cash use and margin compression — gross profit and operating results contracted year-over-year and operating cash flow was negative for the quarter, raising near-term execution and margin concerns. QuiverQuant: Q4 2025 Earnings

Institutional Investors Weigh In On Medifast

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets boosted its position in shares of Medifast by 103.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,338 shares of the specialty retailer’s stock worth $32,000 after purchasing an additional 1,187 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Medifast in the 3rd quarter valued at $37,000. Intesa Sanpaolo Wealth Management purchased a new stake in Medifast during the 4th quarter valued at about $47,000. State of Wyoming acquired a new position in Medifast in the 4th quarter worth approximately $59,000. Finally, Strs Ohio purchased a new position in shares of Medifast during the 1st quarter valued at about $78,000. 95.51% of the stock is owned by hedge funds and other institutional investors.

About Medifast

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.